Gritstone Oncology Inc

Gritstone bio, Inc. clinical-stage biotechnology company, which engages in developing the next generation of cancer immunotherapies to fight multiple cancer types. The company was founded by Andrew Allen, Timothy Chan, Mark Cobbold, Graham Lord, Naiyer Rizvi and Jean-Charles Soria in August 2015 and is headquartered in Emeryville, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Gritstone Oncology reports strong financials and promising advancements in immunotherapy

Gritstone Oncology Inc showcases financial stability, progress in cancer immunotherapy, and advancements in infectious disease programs. Challenges include data requirements for ongoing studies, while opportunities lie in upcoming data presentations and exploring novel vaccine concepts.

Gritstone Oncology excels in Q1 with promising GRANITE program and samRNA advancements

Gritstone Oncology's Q1 2023 earnings call highlighted strong financials, progress in the GRANITE program, and advancements in the samRNA platform. Challenges include endpoint selection for Phase 3 study and managing pseudo progressors. Opportunities lie in combining immunotherapies for KRAS mutations and exploring adjuvant settings.

Gritstone Oncology reports positive Q1 results and eyes market expansion

Gritstone Oncology's Q1 2024 performance showcased positive outcomes in the GRANITE program and financial stability through strategic funding.
The company's strengths lie in promising immune responses, encouraging PFS data, and a proactive approach to clinical program advancement.
Challenges include data gaps in patient groups and uncertainties around future consortium data, while opportunities abound in market expansion and upcoming data releases.
Overall, Gritstone Oncology's focus on innovative cancer vaccine programs and financial prudence positions them well for future growth and clinical success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bitfarms Ltd

Ur-Energy

The central idea behind cheap speculative stocks under $3 is simple: small-capitalization investments may lever a greater potential for outsized returns. Of course, that depends greatly on the stars aligning perfectly, which rarely happens.

3 Speculative Stocks You Can Buy for $3 or Less

NEW YORK, NY / ACCESSWIRE / March 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Gritstone bio, Inc. ("Gritstone") (NASDAQ:GRTS) concerning possible violations of federal securities laws. Gritstone issued a press release, on February 29, 2024, "announc[ing] an approximately 40% reduction of its workforce", stating that "[t]he move comes following the recently announced delay of the proposed CORAL Phase 2b study, which resulted in Gritstone not receiving external funding it previously anticipated beginning in 1Q 2024, associated with the initiation of the study.

Did Gritstone bio, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate – GRTS

NEW YORK, NY / ACCESSWIRE / March 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Gritstone bio, Inc. ("Gritstone") (NASDAQ:GRTS) concerning possible violations of federal securities laws. Gritstone issued a press release, on February 29, 2024, "announc[ing] an approximately 40% reduction of its workforce", stating that "[t]he move comes following the recently announced delay of the proposed CORAL Phase 2b study, which resulted in Gritstone not receiving external funding it previously anticipated beginning in 1Q 2024, associated with the initiation of the study.

Levi & Korsinsky Announces an Investigation on Behalf of Gritstone bio, Inc. (GRTS) Shareholders Who May Have Been Affected by Fraud

Gritstone bio Inc. (GRTS) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.30 per share a year ago.

Gritstone bio Inc. (GRTS) Reports Q4 Loss, Tops Revenue Estimates

NEW YORK, NY / ACCESSWIRE / March 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Gritstone bio, Inc. ("Gritstone") (NASDAQ:GRTS) concerning possible violations of federal securities laws. Gritstone issued a press release, on February 29, 2024, "announc[ing] an approximately 40% reduction of its workforce", stating that "[t]he move comes following the recently announced delay of the proposed CORAL Phase 2b study, which resulted in Gritstone not receiving external funding it previously anticipated beginning in 1Q 2024, associated with the initiation of the study.

GRTS ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Gritstone bio, Inc.

-- Preliminary data from Phase 2 portion of Phase 2/3 study evaluating GRANITE, Gritstone's personalized cancer vaccine in front-line metastatic, microsatellite-stable colorectal cancer (MSS-CRC) remain expected in 1Q 2024 -- -- National Cancer Institute-led Phase 1 study evaluating Gritstone's "off-the-shelf" cancer vaccine, SLATE, combined with neoantigen cell therapy expected to begin in the coming months --

Gritstone bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

EMERYVILLE, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced that it is now preparing to launch the Phase 2b head-to-head trial of its next-generation COVID-19 vaccine in the Fall of 2024 rather than 1Q24. This is to allow use of fully GMP-grade raw materials in the vaccine, which is expected to increase the regulatory utility of the trial.

Gritstone bio Announces Update to Comparative Phase 2b COVID-19 Clinical Trial

Asure Software

Syros Pharmaceuticals

A company's size does not necessarily dictate the size of it's returns. On the contrary, if their jobs are done correctly, these penny stocks with potential can generate exponential returns that will undoubtedly benefit your investments.

3 Once-in-a-Lifetime Penny Stocks With Unprecedented Surge Potential

EMERYVILLE, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced that management will be participating in the following investor conference:

Gritstone bio to Participate in Upcoming Investor Conference

Gritstone bio's strength lies in its best-in-class antigen prediction driven by its proprietary AI platform called EDGE. The company employs next-generation vectors, including ChAd and samRNA, to induce strong and durable immune responses. Gritstone is collaborating with Gilead for a vaccine-based immunotherapy for HIV, with a deal value reaching up to $785M.

Gritstone bio: Looking For Validation In 2024

Gritstone bio Inc. (GRTS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Gritstone bio Inc. (GRTS) Upgraded to Buy: What Does It Mean for the Stock?

GRTS's COVID-19 vaccine may produce more durable immunity than current mRNA vaccines, according to data from phase 1 studies. GRTS has secured a $433 million contract with BARDA to conduct a phase 2b study comparing its COVID-19 vaccine with an approved vaccine. GRTS is reporting data from the phase 2/3 GRANITE study of its cancer vaccine in Q1'24.

Gritstone bio: Renewed Excitement For Its COVID-19 Vaccine

-- High neutralizing antibody (nAb) responses sustained through at least 12 months, highlighting potential for durable clinical protection -- -- T cell responses to Spike plus other viral targets observed in all Phase 1 studies, demonstrating broad and potentially variant-proof immune response --

Presentations at IDWeek 2023 Highlight Potentially Differentiated Immunogenicity of Gritstone bio's Next Generation COVID-19 Vaccine

EMERYVILLE, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced results from all three (3) Phase 1 studies evaluating its self-amplifying mRNA (samRNA) vaccine candidates against COVID-19 (part of the company's CORAL program) are to be presented at IDWeek 2023, occurring October 11-15, 2023, in Boston, MA. Last week, Gritstone bio announced a contract with the Biomedical Advanced Research and Development Authority (BARDA) to advance the program into a 10,000 patient, randomized Phase 2b comparative study against COVID-19. The agreement was awarded as part of ‘Project NextGen,' an initiative by the U.S. Department of Health and Human Services (HHS) to advance a pipeline of new, innovative vaccines and therapeutics providing broader and more durable protection for COVID-19.

Gritstone bio Announces Presentations from Phase 1 Studies Evaluating Next-Generation Vaccine Candidate for COVID-19 at IDWeek 2023

Farfetch

Infinera

Iris Energy Ltd

SoundHound AI Inc

With the extreme volatility in today's stock market, gaining an edge requires more than just a list of penny stocks to watch. Investors need to leverage the right tools and resources.

5 Penny Stocks To Buy According To Analysts, Targets Up To 560%

Gritstone bio on Wednesday secured a $433 million contract by the U.S. government to conduct a mid-stage study of its self-amplifying mRNA COVID-19 vaccine candidate.

Gritstone bio wins $433 million US award for COVID vaccine study

Gritstone bio Awarded BARDA Contract to Conduct Comparative Phase 2b Study Evaluating Next-Generation Vaccine Candidate for COVID-19 Valued at up to $433M

Gritstone bio Awarded BARDA Contract to Conduct Comparative Phase 2b Study Evaluating Next-Generation Vaccine Candidate for COVID-19 Valued at up to $433 Million

EMERYVILLE, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced that management will be participating in the following investor conferences:

Gritstone bio to Participate in Upcoming Investor Conferences

Agreement provides nonexclusive access to Genevant's leading LNP technology for use with Gritstone bio's self-amplifying RNA technology in wide array of infectious disease vaccines

Gritstone bio and Genevant Sciences Announce Option and License Agreement

-- Enrollment completed in Phase 2 portion of Phase 2/3 study evaluating GRANITE (personalized cancer vaccine [PCV]) in first-line metastatic microsatellite-stable colorectal cancer (MSS-CRC); preliminary efficacy data expected in 1Q 2024 -- -- Gritstone partnering with Friends of Cancer Research (Friends) on Friends' ctDNA for Monitoring Treatment Response (ctMoniTR) Project, a collaborative research initiative to inform use of ctDNA change as surrogate for survival benefit --

Gritstone bio Reports Second Quarter 2023 Financial Results and Provides Corporate Updates

EMERYVILLE, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world's most potent vaccines, today announced that the company has joined the ctMoniTR Project, a collaborative research initiative providing foundational evidence to inform future use of change in circulating tumor DNA (ctDNA) as an early indicator of long-term clinical benefit from therapeutics in cancer patients. The ctMoniTR Project is led by Friends of Cancer Research (Friends).

Gritstone bio Partners with Friends of Cancer Research (Friends) on the ctDNA to Monitor Treatment Response (ctMoniTR) Project

-- Potent and durable immunogenicity achieved with low dose self-amplifying mRNA vaccine (samRNA) candidate -- -- Immunity boosted for at least 6 months in previously vaccinated-older adults (administration post-primary series of Vaxzevria®, Comirnaty® or Spikevax®) --

Gritstone bio Announces Publication of Interim Results from Phase 1 Study of Self-amplifying mRNA (samRNA) Vaccine Against COVID-19 in Nature Communications

Gritstone bio, Inc. (NASDAQ:GRTS ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 AM ET Company Participants George MacDougall - Director, Investor Relations and Corporate Communications Andrew Allen - Co founder, President and Chief Executive Officer Celia Economides - Executive Vice President and Chief Financial Officer Conference Call Participants Marc Frahm - TD Cowen Ted Tenthoff - Piper Sandler Jonathan Miller - Biotech and Pharmaceuticals Mayank Mamtani - B. Riley Securities Sean Lee - HC Wainwright Operator My name is Erika and welcome to Gritstone bio First Quarter 2023 Earnings Conference Call.

Gritstone bio, Inc. (GRTS) Q1 2023 Earnings Call Transcript

Gritstone bio Inc. (GRTS) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.34 per share a year ago.

Gritstone bio Inc. (GRTS) Reports Q1 Loss, Lags Revenue Estimates

EMERYVILLE, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced it will report its first quarter 2023 financial results and provide a corporate update following market close on Thursday, May 11, 2023.

News for Gritstone Oncology Inc Stock (GRTS)